Warnings, Recalls: Consumer Health Regulatory News

Rodent feces in Chinese OTC firm’s facility; and Major, Rugby recall Pharmatech-made OTCs.

FDA entrance sign 2016

FDA placed Zhejiang, China, topical OTC drug firm Bicooya Cosmetics Ltd. on import alert until it corrects numerous “significant” good manufacturing practices violations, according to an Aug. 11 warning letter. Bicooyamarkets acne treatments, hand sanitizers, diaper rash lotion and shampoos regulated as OTC drugs. During a May 22-25 inspection, agency officials observed rodent feces throughout the building, including in proximity to a filling machine where OTC drug products are manufactured, and around raw materials and finished drug products, the Center for Drug Evaluation and Research’s Office of Manufacturing Quality stated. Bicooya also failed to clean, maintain and sanitize utensils at appropriate intervals to prevent malfunctions and contamination; did not have appropriate lab determination of satisfactory conformance to final specifications for batches of products – including the identity and strength of each active ingredient – prior to release; and failed to prepare batch production and control records with complete information relating to production and control of each batch of drug produced. FDA inspectors also observed facility staff altering information in analytical test reports during inspection.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Manufacturing

Aragen’s CEO Says NIH Funding Cut Means Less R&D Money, And Tariffs Would Add To Woes

 
• By 

Aragen’s CEO Manni Kantipudi, who is keenly watching the Trump Administration’s moves on pharma tariffs, discusses funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, and talks with the Indian government to solve intellectual property challenges in an interview.

US FDA Retirements Continue Unabated With Drug Inspectorate Leaders, Former Chief Counsel

 

Alonza Cruse, director of the Office of Human and Animal Drugs Inspectorate, and two other senior inspection officials are departing, along with Mark Raza, chief counsel from 2021 until January.

Companies Advised To Assess Potential Impacts Of Landmark Global Pandemic Treaty

 

Mechanisms in the draft treaty that the more than 190 member states of the World Health Organization have finally agreed to are expected to “materially affect companies,” particularly those that develop, manufacture or distribute pandemic-related health care products.

ICH Modernizes Stability Testing Guideline

 
• By 

The International Council for Harmonisation has consolidated and modernized its existing stability guidelines into one document, and addressed modern stability testing approaches like modeling, bracketing, and matrixing.

More from Compliance

Beyond Tariffs: The Silver Lining Of The US Pharma Security Investigation

 

An investigation by the US Secretary of Commerce into pharmaceutical imports gives industry an opportunity to comment. AAM CEO John Murphy talked to Pink Sheet's sister publication Scrip about the latest developments.

US FDA’s Advanced Manufacturing Designation Lifts Off With Cellares Cell Shuttle

 

Cellares’ fully automated cell therapy manufacturing platform is the first system to receive an Advanced Manufacturing Technology designation from US FDA

Pharma Still Nervous While Riding Trump’s Tariff Rollercoaster

 

The rollout of Trump’s plan has been a policy whiplash, but despite a 90-day pause on tariffs, the US president still appears to be holding a grudge with industry over drug pricing.